NYSE:OGEN
Oragenics Inc.
Oragenics Inc. reported net income of −$9.8M in fiscal 2025. The diluted share count rose 877.2%.Summary generated from Oragenics Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−243.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+877.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | n/a | n/a |
| Operating income | −16 | −14 | −21 | −11 | −9 |
| Net income | −16 | −14 | −21 | −11 | −10 |
| Free cash flow | −14 | −15 | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Sep 16, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 4Insider transaction report
Jul 7, 2026 - 8-KEntry into a material agreement
Jul 6, 2026 - DEF 14AProxy statement
May 20, 2026 - 8-KRegulation FD disclosure
May 19, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026